WO2011142588A9 - 피부결함의 완화 또는 치료를 위한 자가피부세포치료제의 제조방법 - Google Patents
피부결함의 완화 또는 치료를 위한 자가피부세포치료제의 제조방법 Download PDFInfo
- Publication number
- WO2011142588A9 WO2011142588A9 PCT/KR2011/003474 KR2011003474W WO2011142588A9 WO 2011142588 A9 WO2011142588 A9 WO 2011142588A9 KR 2011003474 W KR2011003474 W KR 2011003474W WO 2011142588 A9 WO2011142588 A9 WO 2011142588A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- cells
- cell
- tissue
- cell therapy
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Definitions
- the present invention relates to a method for producing an autologous skin cell therapy for alleviating or treating skin defects. More specifically, unlike a conventional cell therapy, a cell therapy can be prepared in a short time by eliminating an enzyme or a culture step. Provide a way.
- Defects in skin tissues such as burns, cuts, and depigmented skin can lead to scarring, prolonged periods of treatment, and other skin diseases if not properly treated or improperly treated.
- the conventional method for producing a cell therapeutic agent using autologous cells uses a method of harvesting specific cells by treating an enzyme and culturing the collected cells for several days. Therefore, the conventional cell therapy has a problem in that it is not suitable for a patient who takes a long time to incubate the cell and the degree of skin defect such as burn is serious and urgently needs treatment.
- an object of the present invention is a method for producing a cell therapy for alleviating or treating skin defects using autologous skin cells that are not isolated by enzymatic treatment, and for preparing cell therapy and cell therapy prepared by the above method. To provide a device.
- the above object is, according to the present invention, a method for producing a cell therapy for alleviating or treating skin defects, comprising the steps of: obtaining normal skin tissue at one donor site derived from autologous skin tissue; Grinding the obtained normal skin tissue into cells; It can be achieved by providing a method for producing a cell therapy comprising the step of obtaining a skin cell group comprising at least any one of keratinocytes, melanocytes and fibrous cells from the tissue lysate after the grinding.
- the grinding step may be a step of grinding the normal skin tissue by cell units using a tissue grinder for 10 to 60 seconds per 1 cm 2 of the normal skin tissue size.
- the grinding step may be a step of grinding the normal skin tissue so that the concentration of the ground cells is 1 to 40 x 10 7 / cm 2 .
- the obtained keratinocytes may be included in 60 to 90% of the total acquired cells.
- the obtained melanocytes may be contained in 1 to 5% of the total obtained cells.
- the obtained fibrous cells may be included in 10 to 40% of the total obtained cells.
- the acquiring step may be characterized in that the skin cell group including the obtained keratinocytes, melanocytes and fibroblasts is not cultured.
- the acquiring step may be characterized in that it does not perform any enzyme treatment for acquiring a skin cell group including at least one of the keratinocytes, melanocytes and fibroblasts.
- the skin defect may include any one selected from the group consisting of skin wounds, wounds, skin scars, depigmented skin wounds due to burns.
- the above object can be achieved by a cell therapy prepared by the method for producing a cell therapy described above.
- the cells separated from the cells by enzymatic treatment of autologous skin cells are also isolated. It can be prepared as a cell therapy without performing the culturing step, and has an effect that can be easily and quickly applied to the affected area.
- the present invention even if the normal skin tissue obtained from the subject is a small amount, it has the effect of producing a cell therapy that can be applied to a wide affected area.
- FIG. 1 is a flow chart showing a method for producing a cell therapy according to an embodiment of the present invention
- FIG. 2 is a diagram showing an example of a hemocytometer
- 3a to 3b is a view showing the result of confirming the cell size of the cell therapy prepared according to an embodiment of the present invention
- Figure 4 is a view showing the clinical effect on the burn site of the cell therapy prepared according to an embodiment of the present invention
- FIG. 5 is a view showing another clinical effect on the burn site of the cell therapy prepared according to an embodiment of the present invention.
- Figure 6a is a view showing the electron microscope confirmation results of the cells isolated by the conventional enzyme treatment
- Figure 6b is a view showing the results of the electron microscope confirmation of the isolated cells according to an embodiment of the present invention.
- FIG. 7 is a view showing the effect of the animal experiment on the burn of the cell therapy prepared according to an embodiment of the present invention.
- FIG. 8A is a view showing H & E staining results of the image part of FIG. 7;
- FIG. 8B is a view illustrating MT staining results of the image part of FIG. 7;
- FIG. 9 is a view showing the effect of animal testing on the wound of the cell therapy prepared according to an embodiment of the present invention.
- Figure 10a is a view showing the MT staining result after applying the control to the wound of Figure 9,
- Figure 10b is a diagram showing the MT staining result after applying the cell therapy prepared according to an embodiment of the present invention to the wound site of Figure 9.
- FIG. 1 is a flowchart of a method for producing a cell therapy agent of the present invention.
- the method for producing a cell therapy of the present invention comprises the steps of acquiring normal skin tissue at one donor site derived from autologous skin tissue (S11); Grinding the obtained normal skin tissue into cells (S12); And obtaining a skin cell group including at least one of keratinocytes, melanocytes, and fibrous cells from the tissue lysate after the grinding (S13).
- Method for producing a cell therapy of the present invention is a method for producing a cell therapy for the relief or treatment of skin defects in mammals.
- the present invention relates to a method for preparing a cell therapy agent for alleviating or treating skin defects in humans.
- the acquiring step of the normal skin tissue may be obtained from the subject by using a skin extractor (Dermatome).
- the subject may include a mammal or a human.
- the normal skin tissue can be obtained by cutting to a size of (1 to 5mm) x (1 to 5mm), the number of tissue having the size can be obtained in consideration of the size of the affected area, for example the size It is possible to obtain 1 to 30 pieces, more preferably 5 to 25 pieces, and even more preferably 10 to 25 pieces.
- the obtained normal skin tissue can be used by washing with physiological saline or annihilate.
- the washed tissue can be used by sterilization using conventional methods.
- the grinding of the normal skin tissue is a step of grinding the obtained normal skin tissue in units of cells.
- the milling can be carried out using a conventional tissue mill that can typically mill the tissue.
- tissue When the tissue is pulverized, a small amount of physiological saline or sterile water may be pulverized in consideration of the amount of the tissue to be pulverized, and preferably 1-10 cc, more preferably 1-5 cc of physiological saline or sterile water is added. Can be pulverized.
- the grinding time can be set in consideration of the amount of the tissue, preferably 1 to 60 seconds per 1 cm 2 of the tissue size, more preferably 10 to 60
- the tissue can be milled cell-by-cell for seconds.
- the tissue may be pulverized such that the concentration of the pulverized cells is (1 to 40) x10 7 cells / cm 2 .
- the concentration of the cells may vary depending on the age of the subject or the condition of the tissue.
- the acquiring of the skin cell group means acquiring a skin cell group including at least one of keratinocytes, melanocytes, and fibrous cells from the tissue lysate after the grinding.
- the keratinocytes are keratinocytes that produce keratin and create physical barriers to protect individuals from harmful factors from the outside, and produce and secrete various biological response modulators that regulate immunological responses. It is an important component in regulating immune and inflammatory responses.
- the melanocytes are cells that produce melanin, a brown or black pigment present in animal tissues and skin, and continuously send melanin granules made in the cells to epidermal cells. The higher the amount, the more the skin color becomes yellowish brown to blackish brown, and the smaller the color becomes, the thinner the color becomes.
- the fibroblasts also called fibroblasts, are cells that form an important component of fibrous connective tissue and are flat and elongated when viewed with tissue sections and often have irregular projections.
- the acquiring step is to obtain a skin cell group including the keratinocytes, melanocytes, and fibrous cells from the tissue lysate after crushing the tissue.
- the obtained skin cell group including at least one of keratinocytes, melanocytes, and fibrous cells may include not only cells that have survived but also cells that are destroyed in the grinding step.
- the obtained keratinocytes may be included in 60 to 90% of the total acquisition cells, the obtained melanocytes may be included in 1 to 5% of the total acquisition cells, the acquisition The fibroblasts can be included in 10 to 40% of the total acquired cells.
- a method capable of separating keratinocytes, melanocytes, or fibrous cells from the normal skin tissue without treating any enzyme there is provided a cell therapeutic agent which can be directly applied to the affected area without culturing a skin cell group including at least one of the obtained keratinocyte melanocytes and fibrous cells.
- the cell therapy prepared by the manufacturing method according to the present invention is excluded from the cell separation process by the enzyme treatment, and the culture process of the separated cells is excluded, so that can be prepared in a very short time and immediately after the preparation to the affected area It is very effective to apply.
- the skin defect may include any one selected from the group consisting of skin wounds, wounds, skin scars, depigmented skin wounds due to burns.
- Normal skin tissues were obtained by cutting a skin tissue of 4x5mm size from a 47-year-old female and a 36-year-old female, each 20 using a skin extractor, washed with physiological saline, and sterilized. The sterilized tissue was pulverized for about 30 seconds using a tissue grinder with the addition of 2cc of sterile water.
- a 47-year-old female autologous skin cell was obtained by obtaining a skin cell group including at least one of keratinocytes, melanocytes, and fibrous cells from tissue lysates using a cell strainer. Cell therapy and cell therapy using autologous skin cells of 36 year old women were prepared.
- the hemocytometer has two chambers, which are divided into regular squares by slide glass with horizontal and vertical hatchings on the surface thereof, and microscopically examine cells existing in a constant volume rectangular section of each chamber. The number of cells can be counted under to determine the concentration of cells present in the entire sample.
- the concentration of the cells was measured by the following Equation 1.
- Cell concentration of the cell concentration of the measurement result is a cell concentration of cell therapy using about 1.4x10 8 cells were, 36-year-old female self skin cells per cm2 is 2.4x10 8 cells It was confirmed.
- the size of the keratinocytes, melanocytes, and fibroblasts of the 47-year-old female autologous skin cells and the 36-year-old autologous skin cells were determined.
- the procedure of the cell size confirmation experiment followed the general experimental procedure.
- the size of primary cells that is, normal cells, was confirmed.
- the cell size was confirmed under a microscope.
- FIG. 3a is a result of observing primary cells under a microscope as a comparative example
- FIG. 3b is a result of observing a cell size of a cell therapy prepared using autologous skin cells of the 36-year-old woman
- FIG. 3c is The cell size of a 47-year-old woman using autologous skin cells was observed under a microscope.
- the primary cell in the case of the primary cell (comparative example) is the size of 10-25 um
- the cells included in the cell therapy using autologous skin cells of the 36-year-old The size was 6-15 um
- the size of the cells included in the cell therapy product using the autologous skin cells of the 47 year old female was also confirmed to be 6-15um. Therefore, it can be seen that the cell size included in each of the 47- and 36-year-old female cell therapy products using autologous skin cells is included in the range of the size of the cells.
- the survival rate of the cells contained in the 47-year-old female autologous skin cells and 36-year-old autologous skin cells were confirmed. 100 ⁇ l of each cell therapeutic agent 100 ⁇ l trypan blue was added and mixed well, and then slowly injected into a hemocytometer covered with a cover glass (see FIG. 2). After about 1 minute, the cell viability was calculated using the following equations (2) to (4) by measuring the number of cells (dead cells) and cells not dyed (surviving cells) that were stained under a microscope.
- the cell survival rate of the 47-year-old female cell therapy using autologous skin cells was 72%, 36-year-old female was 72.5%, showing a high cell viability.
- the burn affected tissue tissue adhesive (fibrin) first, and then sprayed and bandaged the cell therapy using the autologous skin cells. After applying the cell therapy, the state after 7 days was examined.
- the method for producing a cell therapeutic agent of the present invention can be prepared without undergoing a step such as enzyme treatment and / or cell culture, and can be prepared in a fairly simple and fast time and immediately applied to the affected area, requiring urgent need. It can have a significant effect on the application of patients with skin defects.
- Experimental Example 2 affected part 2 of the cell therapy prepared according to an embodiment of the present invention
- Normal skin tissue from a 49-year-old male was obtained by cutting 20 pieces of skin tissue using a skin extractor, washed with physiological saline, and sterilized. The sterilized tissue was pulverized for about 30 seconds using a tissue grinder with the addition of 2cc of sterile water.
- cell strainer cell strainer
- the 49-year-old male was first sprayed with a biotissue adhesive (fibrin), and sprayed and bandaged with a cell therapy including autologous skin cells. After applying the cell therapy, the state after 10 days, 30 days, and 155 days was examined.
- FIG. 5A is a photograph photographing a state immediately after an image of a 49-year-old male. 10 days after spraying the cell therapeutic agent containing the autologous skin cells to the burn site of (A) is in Figure 5 (B), 30 days after spraying is in Figure 5 (C), The state after 100 days after spraying is as shown in FIG. For this reason, it was confirmed that the skin cell regeneration of the burned site was well performed by only one spray of the cell therapeutic agent including autologous skin cells prepared according to the method of the present invention.
- the use of the cell therapy according to the present invention can be expected to have a preventive effect on the skin pigmentation abnormality often occurs due to burn pigment due to a small difference in pigmentation between the burn and normal skin. Is so soft that fewer graft scars remain than those implanted.
- the cell therapy agent according to the production method of the present invention includes physically separated cells. Accordingly, the physically separated cells and the enzyme-separated cells were identified by electron microscopy.
- Figure 6a is an electron micrograph of the cells separated by the enzyme
- Figure 6b is an electron micrograph of the autogenous skin cells of 49-year-old male prepared in Experimental Example 2.
- cells are attached to each other by binding molecules.
- the enzyme will cut the cell adhesion molecules, so that the shape of each cell can be very clean.
- the cells included in the cell therapy according to the present invention are not separated by enzymatic treatment but physically separated, it is confirmed that the cell adhesion molecule is not cut but is still attached to the separated cells as shown in FIG. 6B.
- the cell therapy agent of the present invention is sprayed on the affected area, it is determined that the cell adhesion molecule is well attached to the affected tissue of the affected area to help skin regeneration.
- control site and the test group were first applied to the burn site of the nude let, and the burn site was subjected to general dressing for 7 days, and the biopsy was performed at the expense of the nude hat after 14 days.
- a tissue block using paraffin was prepared as the animal tissue of the burn site, and the tissue was cut into thin sections and attached to the slide to allow staining.
- the slides were observed by H & E (Haematoxylin and eosin stain) staining for observation of new tissues and cells, and then read and read.
- collagen staining was observed and read by MT stain (Masson's trichrome) staining method.
- Fig. 7 shows an example of application of the cell therapy agent of the present invention to a burn site of a nude rat.
- FIG. 7 is a photograph showing the image portion of the nude let.
- (B) is a picture taken 14 days after spraying the control to the burn site of the nude let
- (D) is a picture taken 14 days after spraying the experimental group on the burn site of the nude let.
- Figure 8a is a view showing the results of the haematoxylin and eosin stain (H & E) staining.
- H & E haematoxylin and eosin stain stain stain staining.
- A is a photograph obtained by performing normal skin cells H & E staining for comparison of the control group and the experimental group.
- B shows the results of H & E staining when the control group was applied to the burn site, and it was confirmed that the photographs of the normal cells and the test group were significantly different from the photograph (C) of the H & E staining results.
- 8b is a diagram showing the results of MT stain (Masson's trichrome) staining.
- test group to which the cell therapy of the present invention was applied as compared to the control group was found to be remarkably superior in epithelialization, skin appendage and regeneration of collagen.
- control site and the test group were first sprayed onto the wound site of the nude let, and the wound site was subjected to a general dressing for 3 days, and the biopsy was performed at the expense of the nude let after 7 days.
- the wound was observed by staining collagen with MT satin staining, and the staining was performed in the same manner as in the above Experiment 4-1.
- FIG. 9 is a view showing an application of the cell therapy of the present invention to the wound site of the nude rat.
- FIG. 9 is a photograph showing the wound portion of the nude let.
- (B) is a picture taken 7 days after spraying the control to the wound site of the nude let
- (D) is a picture taken 7 days after spraying the experimental group to the wound site of the nude let.
- the control group using saline epithelial cells were not regenerated at the wound site, but in the experimental group to which the cell therapy product of the present invention was applied for 7 days, the wound area was pale red. However, the epithelial cells have been shown to be regenerated, and the skin regeneration at the wound site was remarkably superior.
- 10A is a result of MT staining when the control group was applied to the wound site, immediately after the wound (A), 7 days after the control application (B), and 200-fold magnification (C) of the a site.
- Figure 9a only in the control group using physiological saline, the formation of epithelialization at the wound site was low (B), very little of the MT stained collagen (C).
- 10b is a result of MT staining when the experimental group is applied to the wound site, immediately after the wound (A), 7 days after the experimental group is applied (B), and 200-fold magnification (C) of the b site.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (10)
- 피부 결함의 완화 또는 치료용 세포치료제의 제조방법으로서,자가 피부조직에서 유래된 하나의 공여부위에서 정상피부조직을 획득하는 단계와;상기 획득한 정상피부조직을 세포단위로 분쇄하는 단계와;상기 분쇄 후 조직 파쇄물로부터 각질형성세포, 멜라닌색소세포 및 섬유세포 중 적어도 어느 하나를 포함하는 피부세포군을 획득하는 단계를 포함하는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 분쇄단계는, 상기 정상피부조직 크기의 1 cm2 당 10 내지 60초 동안 조직분쇄기를 이용하여 상기 정상피부조직을 세포단위로 분쇄하는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 분쇄단계는, 상기 분쇄된 세포의 농도가 1내지 40x107 개/cm2가 되도록 상기 정상피부조직을 분쇄하는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 획득단계는, 상기 획득된 각질형성세포는 전체 획득 세포의 60 내지 90%로 포함되는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 획득단계는, 상기 획득된 멜라닌색소세포는 전체 획득 세포의 1 내지 5%로 포함되는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 획득단계는, 상기 획득된 섬유세포는 전체 획득 세포의 10 내지 40%로 포함되는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 획득단계는, 상기 획득한 각질형성세포 멜라닌색소세포 및 섬유세포 중 적어도 어느 하나를 포함하는 피부세포군을 배양하지 않는 것을 특징으로 하는 세포치료제의 제조방법.
- 상기 획득단계는, 상기 각질형성세포, 멜라닌색소세포 및 섬유세포 중 적어도 어느 하나를 포함하는 피부세포군을 획득하기 위하여 효소 처리를 수행하지 않는 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항에 있어서,상기 피부 결함은, 화상, 창상, 피부 흉터, 탈색소된 피부상처로 구성된 군에서 선택되는 어느 하나인 것을 특징으로 하는 세포치료제의 제조방법.
- 제1항 내지 제9항 중 어느 한 항의 방법에 따라 제조된 세포치료제.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800228845A CN103037871A (zh) | 2010-05-11 | 2011-05-11 | 用于缓解或治疗皮肤缺损的自体皮肤细胞治疗剂的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0044179 | 2010-05-11 | ||
KR20100044179 | 2010-05-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2011142588A2 WO2011142588A2 (ko) | 2011-11-17 |
WO2011142588A3 WO2011142588A3 (ko) | 2012-04-19 |
WO2011142588A9 true WO2011142588A9 (ko) | 2012-06-07 |
Family
ID=44914822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/003474 WO2011142588A2 (ko) | 2010-05-11 | 2011-05-11 | 피부결함의 완화 또는 치료를 위한 자가피부세포치료제의 제조방법 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101328561B1 (ko) |
CN (1) | CN103037871A (ko) |
WO (1) | WO2011142588A2 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104611289A (zh) * | 2015-01-13 | 2015-05-13 | 广州赛奕德生物技术有限公司 | 自体表皮细胞和成纤维细胞同时制备方法及其生物美容产品 |
CN107961061A (zh) * | 2017-12-19 | 2018-04-27 | 济南磐升生物技术有限公司 | 一种自体皮肤创伤治疗仪 |
KR102427018B1 (ko) * | 2019-06-11 | 2022-07-29 | 재단법인 베스티안재단 | 피부치료제의 제조방법 및 이로부터 얻어지는 피부치료제 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8394371B2 (en) | 2002-02-11 | 2013-03-12 | Neocutis Sa | Compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same |
US7641898B2 (en) * | 2003-03-21 | 2010-01-05 | Materials Evolution And Development Usa, Inc. | Keratinocyte-fibrocyte concomitant grafting for wound healing |
KR100806695B1 (ko) * | 2005-11-25 | 2008-02-27 | 주식회사 엠씨티티 | 색소화 질환 치료용 세포치료 약제학적 조성물 |
-
2011
- 2011-05-11 CN CN2011800228845A patent/CN103037871A/zh active Pending
- 2011-05-11 WO PCT/KR2011/003474 patent/WO2011142588A2/ko active Application Filing
- 2011-05-11 KR KR1020110043780A patent/KR101328561B1/ko not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO2011142588A3 (ko) | 2012-04-19 |
KR20110124722A (ko) | 2011-11-17 |
KR101328561B1 (ko) | 2013-11-13 |
CN103037871A (zh) | 2013-04-10 |
WO2011142588A2 (ko) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017123022A1 (ko) | 고함량의 성장인자를 함유한 줄기세포 유래 엑소좀 | |
WO2011031077A2 (ko) | 동결보존 무세포 진피 기질의 제조 방법 및 그로부터 제조된 동결보존 무세포 진피 기질 | |
WO2016167527A1 (ko) | 백미 추출물의 지표성분인 시나프산 또는 이를 함유하는 백미 추출물을 함유하는 피부재생용 화장료 조성물 및 상처 치료용 약학 조성물 | |
WO2019004757A9 (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 가려움증 억제 또는 개선 용도 | |
KR101063299B1 (ko) | 줄기세포 배양액을 포함하는 화장료 조성물 | |
WO2021167330A1 (ko) | 수축 제어가 가능한 진피층 개발, 및 이를 이용한 균일한 성능의 인공피부의 제조 | |
WO2021033899A1 (ko) | 히알루론산과 동결건조된 줄기세포 유래 엑소좀의 조합을 유효성분으로 포함하는 창상 치료 또는 창상 치료 촉진용 조성물 | |
WO2022071643A1 (ko) | 에델바이스 유래의 엑소좀을 유효성분으로 포함하는 새로운 조성물 | |
WO2013089449A1 (ko) | 홍삼 먹인 달팽이 점액을 함유하는 화장료 조성물 및 그 제조방법 | |
WO2011142588A9 (ko) | 피부결함의 완화 또는 치료를 위한 자가피부세포치료제의 제조방법 | |
WO2019190200A1 (ko) | 인체 지방줄기세포 배양액 추출물과 피디알앤을 함유하는 화장료 조성물 | |
EP2764091B1 (en) | Diagnostic method for connective tissue and its application | |
WO2021201637A1 (ko) | 제대혈 줄기세포에 의해 고효능의 엑소좀이 고함량으로 분비된 배양액의 제조 방법 및 이의 용도 | |
WO2018143692A1 (ko) | 유근피 또는 유백피 파우더를 유효성분으로 포함하는 창상 치료 및 피부 재생용 약학 조성물 | |
WO2019245332A1 (ko) | 베타글루칸, 글리시틴 및 4',6,7-트리메톡시이소플라본을 포함하는 창상 치료 또는 피부 활성용 약학적 조성물 | |
WO2019088545A1 (ko) | 엑소좀 키트 및 이를 이용한 엑소좀의 경피 투과 증진 방법 | |
WO2019112238A2 (ko) | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피부 보습용 화장료 조성물 | |
Kanerva et al. | Hyperpigmentation and Hypopigmentation of the Skin after Long Term PUVA Therapy: Light and electron microscopic observations on three patients | |
WO2021096089A1 (ko) | 줄기세포 유래 엑소좀과 폴리데옥시리보뉴클레오티드를 유효성분으로 포함하는 새로운 조성물 | |
WO2018056676A1 (ko) | 퍼플콘 추출물을 함유하는 피부 질환의 예방 또는 치료용 약제학적 조성물 | |
WO2021010596A1 (ko) | 산화 그래핀을 유효성분으로 함유하는 화장료 조성물 | |
WO2017171404A1 (ko) | 펜타사이클릭 트리터펜 카페익 액씨드 에스터를 포함하는 피부 보습 또는 피부 미백용 조성물 | |
WO2023172023A2 (ko) | 식물줄기세포 배양추출물과 유산균 엑소좀을 내포하는 오스모셀을 유효성분으로 함유하는 화장료 조성물 | |
WO2023022414A1 (ko) | 아이리스 유래의 엑소좀을 유효성분으로 포함하는 새로운 조성물 | |
CN110237091A (zh) | 一种可用于儿童的透明质酸修护生物膜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180022884.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11780805 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 18.02.2013) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11780805 Country of ref document: EP Kind code of ref document: A2 |